- Home
- MDWD vs FENC Comparison
MDWD vs FENC Comparison
Compare MDWD & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- FENC
- Stock Information
- Founded
- MDWD 2000
- FENC 1996
- Country
- MDWD Israel
- FENC United States
- Employees
- MDWD N/A
- FENC N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDWD Health Care
- FENC Health Care
- Exchange
- MDWD Nasdaq
- FENC Nasdaq
- Market Cap
- MDWD 184.8M
- FENC 172.8M
- IPO Year
- MDWD 2014
- FENC 2001
- Fundamental
- Price
- MDWD $17.75
- FENC $6.08
- Analyst Decision
- MDWD Strong Buy
- FENC Strong Buy
- Analyst Count
- MDWD 1
- FENC 2
- Target Price
- MDWD $25.00
- FENC $14.00
- AVG Volume (30 Days)
- MDWD 56.9K
- FENC 86.4K
- Earning Date
- MDWD 11-26-2024
- FENC 11-07-2024
- Dividend Yield
- MDWD N/A
- FENC N/A
- EPS Growth
- MDWD N/A
- FENC N/A
- EPS
- MDWD N/A
- FENC N/A
- Revenue
- MDWD $19,720,000.00
- FENC $49,348,000.00
- Revenue This Year
- MDWD $10.37
- FENC $107.12
- Revenue Next Year
- MDWD $26.36
- FENC $33.37
- P/E Ratio
- MDWD N/A
- FENC N/A
- Revenue Growth
- MDWD N/A
- FENC 278.09
- 52 Week Low
- MDWD $11.04
- FENC $3.96
- 52 Week High
- MDWD $24.00
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- MDWD 53.40
- FENC 54.24
- Support Level
- MDWD $17.33
- FENC $5.51
- Resistance Level
- MDWD $18.25
- FENC $6.56
- Average True Range (ATR)
- MDWD 0.75
- FENC 0.33
- MACD
- MDWD 0.05
- FENC -0.04
- Stochastic Oscillator
- MDWD 73.68
- FENC 54.29
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.